Semax Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Semax?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Neuroprotection, cognitive enhancement, ischemic stroke recovery, mood regulation, Alzheimer’s disease modeling
• First Developed: 1980s-1990s, Institute of Molecular Genetics, Russian Academy of Sciences
• Molecular Weight: 813.92 g/mol
• Research Status: Approved in Russia for clinical use; classified research-use-only in most other jurisdictions; 100+ published studies
• Key Mechanisms: BDNF/TrkB upregulation, melanocortin receptor modulation, monoaminergic system activation, enkephalinase inhibition, immune and vascular gene expression modulation, copper chelation
• Published Studies: Over 100 published studies; primarily Russian-language and preclinical
• Clinical Trial Status: Russian clinical data exists; no published Phase II or III trials in international peer-reviewed English-language journals
• Regulatory Classification: Approved prescription drug in Russia; research chemical classification in most other countries

What is Semax?

Semax is a synthetic heptapeptide consisting of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It was engineered from positions 4 through 10 of adrenocorticotropic hormone (ACTH), a 39-amino acid pituitary peptide, with a C-terminal Pro-Gly-Pro tripeptide extension added to improve stability and biological activity.

The story of Semax begins with a fundamental pharmacological question: could the cognitive and neuroprotective properties of ACTH be separated from its hormonal effects? ACTH stimulates cortisol production by binding to melanocortin-2 receptors on the adrenal cortex, but researchers at the Institute of Molecular Genetics in Moscow recognized that a central fragment of ACTH independently influenced learning, attention, and neural resilience. The challenge was creating a stable, non-hormonal version of that fragment suitable for research and potential clinical use. The addition of the Pro-Gly-Pro sequence solved the stability problem by introducing proline residues that resist enzymatic degradation, extending the peptide’s biological activity well beyond what the plasma half-life alone would predict.

What emerged was a compound with no adrenal hormone activity at research doses, but with documented effects on brain-derived neurotrophic factor (BDNF), a protein central to neuronal survival, synaptic plasticity, and learning. BDNF is sometimes described as "fertilizer for the brain" because of its role in promoting neuron growth and maintenance. Semax appears to upregulate BDNF and its receptor TrkB in the hippocampus, the brain region most associated with memory formation.

Russian researchers conducted clinical trials through the 1990s and 2000s, leading to regulatory approval in Russia for treating ischemic stroke and cognitive disorders. Semax was added to Russia’s List of Vital and Essential Drugs in 2011, reflecting its integration into standard neurological care within that system. Outside Russia and a small number of Eastern European countries, Semax remains classified as a research compound with no approved therapeutic indication.

Most published research on Semax uses animal models, particularly rats, with intranasal administration. This delivery route mirrors the approved pharmaceutical formulation in Russia and allows peptides to bypass the blood-brain barrier by traveling along olfactory nerve pathways. The human clinical literature exists primarily in Russian-language journals, limiting independent international verification.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Semax contains three proline residues distributed throughout its sequence. Proline is an unusual amino acid whose cyclic structure blocks the peptide bond from adopting the flat, extended conformation that peptidase enzymes require to cleave it. This makes the molecule substantially more resistant to breakdown than a typical seven-amino acid peptide would be, explaining why biological effects persist far longer than the 30-minute plasma half-life in rodent models would suggest.

The methionine at the N-terminal position and the histidine imidazole ring together create a metal-binding site with coordination geometry similar to human albumin. This arrangement allows Semax to form stable complexes with copper(II) ions, a structural feature with direct implications for its studied effects on amyloid-beta aggregation and metal-induced neurotoxicity.

Phenylalanine at position 4 contributes a hydrophobic aromatic group involved in receptor binding interactions. The glutamic acid residue adds a negatively charged carboxyl group that affects the peptide’s solubility and receptor recognition. The C-terminal glycine within the Pro-Gly-Pro extension acts as a flexible linker between the biologically active core and the stabilizing terminal proline.

Comparing Semax to its parent ACTH fragment clarifies the engineering intent. Native ACTH(4-10) degrades rapidly in plasma and lacks the C-terminal stabilization. Semax retains the neurotropic binding properties of the ACTH core while the PGP extension extends functional duration. Critically, neither the native fragment nor Semax activates MC2 receptors or stimulates cortisol production, separating the neuropeptide activity from the hormonal activity of the full ACTH molecule.

Mechanisms of Action Being Investigated

Semax operates through multiple interconnected biological pathways rather than a single defined receptor target. Researchers classify its effects as pleiotropic, meaning one compound influences several distinct systems simultaneously. The primary mechanism involves BDNF signaling, but at least five additional pathways contribute to the full profile of effects observed in research models.

BDNF and TrkB Receptor Pathway

The most consistently documented mechanism is Semax’s upregulation of brain-derived neurotrophic factor and its primary receptor, TrkB. In rat models receiving intranasal administration at 50 mcg/kg, BDNF protein levels in the hippocampus increased 1.4-fold within three hours. TrkB tyrosine phosphorylation, the activation marker for this receptor, increased 1.6-fold over the same period. At the gene expression level, BDNF mRNA from exon III increased threefold, and TrkB mRNA doubled [1].

The timing is noteworthy. Peak BDNF elevation occurs at three hours post-administration, and this correlates precisely with the peak cognitive enhancement window observed in behavioral studies. Researchers have also characterized specific binding sites in rat basal forebrain cell membranes, finding a dissociation constant of 2.4 nanomolar and maximum binding of 33.5 fmol/mg protein. This binding is calcium-dependent, time-dependent, and reversible, suggesting direct receptor-mediated mechanisms beyond secondary signaling cascades [2].

Neurotrophin gene expression changes begin rapidly. Both NGF and BDNF mRNA levels shift within 20 minutes of administration, with elevation persisting up to eight hours for neurotrophin-related genes. These effects show regional specificity: upregulation predominates in hippocampus, brainstem, and cerebellum, while the frontal cortex shows a modulated rather than simply upregulated pattern [1].

Melanocortin Receptor Interactions

Semax interacts with melanocortin receptor subtypes in ways that differ from its parent ACTH molecule. Research demonstrates competitive antagonist activity at MC4 receptors and competitive antagonist or partial agonist activity at MC5 receptors. MC3 receptors show no antagonistic response. MC4 and MC5 pathways participate in neuroprotection and cognitive processing, suggesting these interactions contribute to Semax’s observed effects independently of the BDNF pathway [3].

The precise binding characteristics at melanocortin receptors require further investigation. The available literature does not fully characterize MC1 and MC2 receptor interactions. The functional contribution of melanocortin modulation relative to BDNF upregulation remains an open question, though these pathways are not mutually exclusive.

Monoaminergic System Activation

Semax activates serotonergic pathways in hippocampal and cortical regions and modulates dopaminergic circuits affecting motivation and attention. Studies in rat models show potentiation of D-amphetamine-induced locomotor activity, a finding that signals caution regarding concurrent use with stimulant compounds in research protocols [4].

These monoaminergic effects contribute to the antidepressant-like and anxiolytic properties observed in behavioral tests. Neurotransmitter balance changes occur rapidly following administration and appear to work in parallel with the slower-developing neurotrophin effects, suggesting Semax produces both immediate and sustained biological responses through different mechanisms.

Enkephalinase Inhibition

Semax inhibits enkephalinase, the enzyme that breaks down enkephalins and other endogenous regulatory peptides, with an IC50 of approximately 10 micromolar. By slowing enkephalin degradation, Semax may extend the activity of endogenous opioid peptides, with possible contributions to analgesic effects observed in electrocutaneous pain models [5]. The clinical relevance of this mechanism remains under investigation, and researchers do not currently identify enkephalinase inhibition as a primary driver of the cognitive or neuroprotective effects.

Immune and Vascular Gene Expression

Genome-wide transcriptome analysis in a permanent middle cerebral artery occlusion rat model revealed that Semax influenced the expression of 96 genes at three hours post-occlusion, with substantially more genes affected at 24 hours. The predominant effect was enhancement of immune response genes, including immunoglobulin-encoding genes, chemokine-related genes, and immune cell mobility factors [6].

At the protein signaling level, Semax inhibits pJNK activation (a pro-apoptotic pathway), activates pCREB signaling (associated with neuronal survival and plasticity), and downregulates matrix metalloproteinase-9 in cortical regions, reducing extracellular matrix degradation during ischemic injury. VEGF pathway genes and blood vessel formation and stabilization genes also show enhanced expression, supporting the vascular recovery findings in stroke models [6].

Copper Chelation and Amyloid-Beta Modulation

The metal-binding properties of Semax create a separate research avenue relevant to Alzheimer’s disease. Semax forms stable copper(II) complexes through its methionine and histidine residues, and this chelation ability allows it to extract copper from Cu(II)-amyloid-beta complexes. In buffer solutions and in model membrane environments containing phospholipids, Semax inhibits amyloid-beta(1-40) fiber formation in a concentration-dependent manner, stabilizes intermediate oligomeric aggregation states, and prevents copper-induced membrane disruption [7].

Cell culture studies show reduced cytotoxicity in neuroblastoma and endothelial cell lines exposed to copper, and rat studies document protective effects against lead-induced oxidative damage. The antioxidant properties appear dose-dependent, and researchers note that substantially more investigation is needed before Semax could be evaluated seriously as an anti-Alzheimer’s candidate.

The primary molecular target for Semax has not been definitively identified. Whether the full range of effects reflects direct receptor binding or downstream cascade activation remains uncertain. The relative contribution of each pathway, the role of active metabolites versus intact peptide, and the basis for regional brain specificity all require further characterization.

Major Areas of Research

Semax research concentrates in five primary areas: cerebrovascular protection, cognitive and memory function, mood and stress response, Alzheimer’s disease modeling, and vision. The depth of evidence differs substantially across these areas, with neuroprotection and cognitive research receiving the most attention.

Cerebrovascular Protection and Stroke Research

Ischemic stroke research represents Semax’s best-characterized and clinically most advanced application. Animal studies using permanent middle cerebral artery occlusion consistently show reduced infarct volume, enhanced neurological recovery in functional tests, and increased neuron survival in penumbral regions, the tissue surrounding the core infarct that is at risk but potentially salvageable [6].

At the gene expression level, three hours after stroke induction, Semax produces measurable shifts in immune, vascular, and neuroprotective gene expression. By 24 hours, the scope of transcriptional change is substantially broader. Reperfusion injury models also show protective effects at the transcriptome level, with enhanced neurotrophin gene expression, suppressed inflammation-related genes, and maintained neurotransmission-associated gene activity [8].

Human clinical data comes primarily from Russian publications. A 2018 study by Gusev and colleagues enrolled 110 stroke patients and administered 6,000 mcg/day of intranasal Semax in two 10-day courses. Patients receiving Semax showed significantly increased plasma BDNF levels, accelerated rehabilitation when combined with early mobilization therapy, improved motor performance on the British Medical Research Council scale, and higher Barthel index scores measuring functional independence compared to conventional therapy alone [9]. Earlier work by the same group in 1997 and 1999 established neuroprotective effects in the acute phase of hemispheric ischemic stroke, though study sizes were smaller and protocols varied.

Key Research Highlights:

• Reduced infarct volume in pMCAO rat models with improved neurological outcome measures
• Transcriptome-level characterization of 96+ gene expression changes in ischemic brain tissue
• Clinical improvement in motor function and independence in 110-patient Russian trial
• BDNF plasma elevation as a measurable biomarker of treatment response in humans

Cognitive Enhancement and Memory Studies

Cognitive research in animals demonstrates Semax’s effects across multiple memory systems and task types. Rats receiving intranasal Semax show enhanced performance in conditioned avoidance reactions following a single dose, improved spatial memory in radial arm maze testing, increased selective attention during information reception tasks, and better memory consolidation across varied learning paradigms [10].

The three-hour window following administration emerges consistently as the period of maximal cognitive effect, matching the timing of peak hippocampal BDNF elevation. This temporal correlation strengthens the mechanistic argument that BDNF upregulation drives the cognitive benefits rather than being an unrelated parallel effect.

Beyond simple learning tasks, Semax research has examined attention and executive function. Studies suggest improvements in focused attention and information processing speed in animals, though the translation of these findings to human cognition involves significant uncertainty given the methodological differences between rodent behavioral paradigms and human neuropsychological testing.

Key Research Highlights:

• Enhanced spatial memory and conditioned learning in multiple rodent paradigms
• Maximal cognitive effect at three hours correlating with peak hippocampal BDNF
• Improvements in attention and information processing in animal models
• BDNF receptor binding characterized with nanomolar affinity in basal forebrain membranes

Mood, Stress, and Anxiolytic Research

Semax shows antidepressant-like and anxiolytic properties in animal models using standardized behavioral assays. In the forced swim test and sucrose preference test, both validated models of depressive-like behavior, Semax-treated animals perform differently from controls in ways consistent with reduced behavioral despair and preserved hedonic response [11].

Chronic stress studies using unpredictable stress paradigms show that Semax attenuates the behavioral consequences of sustained stress exposure and normalizes stress-induced behavioral alterations. These effects connect mechanistically to the serotonergic and dopaminergic system modulation discussed above, as well as to the melanocortin receptor interactions that influence stress response circuits.

The anxiolytic properties have been observed in elevated plus maze testing, a standard rodent anxiety assay. While these results are promising as preclinical signals, no controlled human clinical trial has examined Semax specifically for mood or anxiety disorders.

Key Research Highlights:

• Antidepressant-like effects in forced swim test and sucrose preference paradigms
• Attenuation of chronic unpredictable stress behavioral consequences
• Anxiolytic properties in elevated plus maze testing
• Mechanistic connection to serotonergic and melanocortin pathway modulation

Alzheimer’s Disease Modeling Research

The amyloid-beta modulation research positions Semax as a candidate for investigation in Alzheimer’s disease models. In vitro studies confirm concentration-dependent inhibition of amyloid-beta(1-40) fiber formation, stabilization of oligomeric intermediates, prevention of copper-induced membrane disruption, and reduced cytotoxicity in neuronal cell lines exposed to copper or lead [7].

These copper chelation properties are structurally grounded. The albumin-like coordination geometry created by the methionine and histidine residues provides a competitive binding site for copper that can displace it from amyloid-beta complexes. Whether this activity translates into meaningful slowing of amyloid pathology in living systems has not been demonstrated. No animal model studies of Alzheimer’s disease pathology using Semax have been published in accessible international literature, and researchers studying this area explicitly note that more detailed investigation is needed before any anti-Alzheimer’s evaluation can proceed.

Key Research Highlights:

• In vitro inhibition of amyloid-beta(1-40) fiber formation in buffer and membrane models
• Copper extraction from Cu(II)-amyloid-beta complexes documented
• Neuroprotection against copper and lead cytotoxicity in cell culture
• Mechanistic basis established but animal and human model validation absent

Ophthalmic and Retinal Research

Semax research has extended into ophthalmology, specifically investigating protective effects on retinal cells. The genomic analysis showing regional BDNF and NGF mRNA changes noted differential effects in retinal tissue, and researchers have pursued this signal in dedicated ophthalmic studies. Russian researchers have investigated Semax in optic nerve damage models and glaucoma-adjacent paradigms, though this area has substantially less published literature than the neurological applications. The rationale centers on BDNF’s established role in retinal ganglion cell survival, making any BDNF-upregulating compound a candidate for ophthalmic neuroprotection research.

Key Research Highlights:

• BDNF and NGF mRNA modulation detected in retinal tissue in initial genomic studies
• Optic nerve protection investigated in Russian research programs
• Limited internationally accessible published literature in this application area

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Semax’s primary delivery route in both research and approved clinical use is intranasal administration. This route allows the peptide to travel along olfactory nerve pathways from the nasal epithelium directly to the central nervous system, partially bypassing the blood-brain barrier. Intranasal delivery results in detectable central nervous system activity that would be difficult to achieve via oral administration, given that peptides are generally susceptible to gastrointestinal degradation. The multiple proline residues in Semax confer greater resistance to peptidase breakdown than typical peptides, but oral bioavailability for systemic purposes remains uncharacterized in accessible literature.

Distribution and Metabolism

Plasma half-life in rat models is under 30 minutes for the intact peptide. This short systemic half-life contrasts strikingly with the biological effect duration. BDNF mRNA elevation persists up to eight hours, and behavioral effects peak at three hours. This discrepancy suggests that either tissue-bound peptide remains active after plasma clearance, active metabolites contribute to sustained effects, or the initial receptor binding triggers cascades that outlast the stimulus.

Regional brain distribution shows preferential accumulation in areas relevant to the studied effects: hippocampus, basal forebrain, and brainstem receive particular attention in the published binding characterization literature. Retinal distribution has also been documented, supporting the ophthalmic research direction. The specific tissue-binding mechanisms and whether peptide fragments retain activity have not been fully resolved.

Delivery Methods Under Investigation

• Intranasal administration: The primary and approved route; direct olfactory pathway delivery to CNS; used in both animal studies and Russian clinical formulations
• Subcutaneous injection: Used in some animal studies; systemic distribution confirmed; commonly employed in research protocols requiring precise dosing
• Intraperitoneal injection: Used in rodent research for rapid systemic delivery; provides consistent absorption in animal model contexts

Excretion and Clearance

Semax undergoes clearance through standard peptide metabolic pathways, primarily enzymatic hydrolysis to constituent amino acids. The multiple proline residues slow this process relative to less-stabilized peptides. Renal excretion of metabolic fragments follows standard small peptide clearance patterns. No dedicated excretion studies in humans have been published in internationally accessible literature.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant limitation in Semax research is the near-absence of human clinical trial data in peer-reviewed international English-language journals. The 110-patient Russian stroke trial represents the most substantial human study, but it has not been replicated independently or published in journals with international peer review standards. No Phase I safety pharmacology study has been published in accessible literature, meaning the human dose-response relationship, pharmacokinetic profile, and safety ceiling are formally uncharacterized for most jurisdictions. Long-term effects beyond the 10-day treatment courses used in Russian clinical studies are completely uninvestigated in available published research.

Mechanistic Understanding The primary molecular target for Semax has not been definitively identified. The literature describes multiple active pathways but does not establish their hierarchy or relative contributions. Whether the BDNF effect is a direct consequence of Semax binding to a specific receptor or emerges from a secondary signaling cascade remains unresolved. The contribution of active metabolites to observed biological effects is unknown. Regional brain specificity, meaning why the hippocampus responds differently from the frontal cortex, has not been mechanistically explained.

Methodological Considerations Most preclinical research originates from Russian institutions with limited independent replication in Western research groups. Study protocols vary substantially in dose, delivery route, timing, and outcome measures, limiting cross-study comparison. The permanent MCAO rat model used in stroke research does not fully recapitulate human ischemic stroke pathophysiology. The melanocortin receptor characterization is incomplete, with MC1 and MC2 interactions unassessed in the available literature.

Areas Needing Further Investigation

• Independent replication of Russian preclinical and clinical findings by Western research groups
• Formal human pharmacokinetic characterization including absorption, distribution, metabolism, and excretion data
• Controlled clinical trials for cognitive and mood applications with appropriate comparator arms
• Complete melanocortin receptor binding profile including MC1 and MC2 subtypes
• Long-term safety assessment beyond 10-day exposure windows
• In vivo validation of the amyloid-beta modulation findings in Alzheimer’s disease animal models

Regulatory and Research Status

Current Classification

FDA Status The FDA has not approved Semax for any therapeutic indication. It is classified as an unapproved new drug and is available in the United States for legitimate laboratory research purposes only. FDA has not issued specific guidance documents addressing Semax directly, placing it in the research chemical category for regulatory purposes. Intranasal pharmaceutical formulations available in Russia are not authorized for import or sale in the United States for human use.

WADA Status Semax does not appear on the current WADA prohibited list as a specifically named substance. However, WADA’s catch-all provisions for peptides and peptide hormones may apply depending on context. Athletes subject to anti-doping testing should consult their sport’s governing body rules and obtain qualified legal advice before any research-adjacent use.

Russian Regulatory Status Semax holds approved prescription drug status in the Russian Federation. It is listed on Russia’s List of Vital and Essential Drugs as of 2011 and is available as a pharmaceutical intranasal formulation for stroke treatment and cognitive rehabilitation. Ukraine and several Eastern European countries have authorized similar formulations.

International Perspective Outside Russia and Eastern Europe, Semax is uniformly classified as a research compound. No EU member state has authorized a Semax pharmaceutical product through the EMA regulatory pathway. The compound exists in a regulatory landscape similar to other Russian neuropeptides that have not undergone the Phase I through III trial process required by FDA or EMA for therapeutic approval.

Research Community Approach

Research institutions in Russia have conducted the majority of published Semax work under institutional ethics oversight appropriate to their national research regulatory frameworks. Western research interest has grown in recent years, driven by the mechanistic interest in BDNF modulation and the limited overlap with existing nootropic compounds. All legitimate research involving Semax requires institutional review board oversight, appropriate biosafety protocols, and compliance with applicable national regulations governing peptide research.

Future Research Directions

The critical gap is human pharmacokinetic and safety data from a formal Phase I study. Without this foundation, no clinical development program can advance in jurisdictions requiring international standards of evidence. The BDNF modulation mechanism continues to attract academic interest given BDNF’s central role in depression, cognitive decline, and neurodegeneration. If a Western pharmaceutical sponsor pursued Semax development, the stroke and cognitive rehabilitation indications with the existing Russian clinical data as supportive background evidence represent the most logical starting point.

Key Research Findings

BDNF Upregulation in Hippocampal Tissue

Research Focus: Neurotrophin gene and protein expression following intranasal Semax in rats Key Results: 1.4-fold increase in hippocampal BDNF protein at three hours; threefold increase in BDNF mRNA from exon III; 1.6-fold increase in TrkB phosphorylation; changes detectable within 20 minutes, persisting up to eight hours Significance: Establishes BDNF upregulation as the primary mechanistic signature of Semax activity and provides a measurable biomarker for future clinical studies Limitations: Rodent data only; human BDNF response magnitude and timing uncharacterized [1]

Receptor Binding Characterization in Basal Forebrain

Research Focus: Identification and characterization of Semax binding sites in rat brain membranes Key Results: Specific, reversible, calcium-dependent binding sites confirmed in basal forebrain cell membranes; dissociation constant of 2.4 nanomolar; maximum binding of 33.5 fmol/mg protein Significance: Demonstrates direct receptor-level activity rather than purely indirect effects; nanomolar affinity suggests high specificity Limitations: Receptor identity not definitively established; no human brain binding data available [2]

Transcriptome Analysis in Ischemic Stroke Model

Research Focus: Genome-wide gene expression changes following Semax in permanent MCAO rats Key Results: 96 genes affected at three hours post-occlusion; predominantly immune response, vascular, and neuroprotective gene categories; pJNK inhibition, pCREB activation, and MMP-9 downregulation at protein level Significance: Provides mechanistic depth far beyond previous single-pathway studies; identifies vascular and immune gene modulation as major contributors to neuroprotection Limitations: Single rodent model; specific gene targets require individual validation; human ischemic brain response may differ substantially [6]

Human Stroke Rehabilitation Trial

Research Focus: Clinical efficacy in ischemic stroke patients during rehabilitation Key Results: 110 patients; two 10-day courses of 6,000 mcg/day intranasal Semax; significantly elevated plasma BDNF; improved motor scores on MRC scale; higher Barthel index functional independence scores versus conventional therapy alone Significance: Provides the largest single human dataset for Semax and demonstrates measurable BDNF elevation as a translatable pharmacodynamic marker Limitations: Published in Russian-language literature; no independent replication; no placebo-controlled blinding described; single research group [9]

Amyloid-Beta Fiber Formation Inhibition

Research Focus: In vitro testing of Semax’s copper chelation effects on amyloid-beta aggregation Key Results: Concentration-dependent inhibition of amyloid-beta(1-40) fiber formation in buffer and phospholipid environments; copper extraction from Cu(II)-amyloid-beta complexes; reduced cytotoxicity in neuronal cell lines Significance: Identifies a structurally grounded mechanism for potential Alzheimer’s disease application; copper-binding domain characterized with albumin-like geometry Limitations: Entirely in vitro; no animal model of amyloid pathology tested; researchers themselves note insufficient data for clinical candidate evaluation [7]

Antidepressant-Like and Anxiolytic Effects in Stress Models

Research Focus: Behavioral outcomes in chronic stress and depression paradigms Key Results: Antidepressant-like outcomes in forced swim and sucrose preference tests; attenuation of unpredictable chronic stress behavioral consequences; anxiolytic effects in elevated plus maze Significance: Extends Semax research beyond neuroprotection into mood and stress regulation with defined behavioral endpoints Limitations: Animal behavioral models have imperfect predictive validity for human psychiatric outcomes; no human mood or anxiety trials published [11]

Frequently Asked Questions

What is Semax and where does it come from?

Semax is a synthetic seven-amino acid peptide derived from a fragment of adrenocorticotropic hormone, a naturally occurring pituitary peptide. It was developed by researchers at the Russian Academy of Sciences in the 1980s and 1990s with the goal of isolating the cognitive and neuroprotective properties of ACTH without its hormonal effects. Semax is currently approved as a prescription drug for stroke treatment in Russia, where it has been in clinical use for several decades.

What does Semax research focus on?

Most Semax research investigates its effects on brain-derived neurotrophic factor, a protein critical for neuron health and memory formation, along with neuroprotection following ischemic injury. Studies have also examined cognitive enhancement in animal learning tasks, antidepressant and anxiolytic effects in stress models, and potential relevance to Alzheimer’s disease through its ability to inhibit amyloid-beta fiber formation and chelate copper ions.

Is Semax approved for human use?

Semax is approved as a prescription drug in Russia and some Eastern European countries for treating ischemic stroke and cognitive disorders. Outside these jurisdictions, including in the United States and the European Union, Semax has not been approved for any therapeutic use and is classified as a research compound. No published Phase I, II, or III clinical trials meeting international peer review standards are available in English-language journals.

How does Semax differ from ACTH?

Full-length ACTH stimulates cortisol production by activating melanocortin-2 receptors on the adrenal glands, creating significant hormonal effects. Semax is derived from a fragment of ACTH that does not activate this adrenal pathway at research doses, meaning it does not stimulate cortisol production or activate the hypothalamic-pituitary-adrenal axis. Semax instead interacts with neurotrophin signaling, melanocortin-4 and melanocortin-5 receptors in the brain, and monoaminergic systems.

How long has Semax been studied?

Foundational research on Semax began at the Institute of Molecular Genetics in Moscow in the 1980s. Clinical development in Russia proceeded through the early 1990s, leading to regulatory approval. Over 100 studies have been published examining its mechanisms and effects, with the research literature continuing to grow. Russian clinicians have been using pharmaceutical Semax formulations for over two decades, though this clinical experience has not been fully captured in internationally accessible peer-reviewed publications.

References

1. Dolotov, O.V., Karpenko, E.A., Inozemtseva, L.S., Seredenina, T.S., Levitskaya, N.G., Rozyczka, J., Dubynin, V.A., Alfeeva, L.Y., Andreeva, L.A., Engele, J., Myasoedov, N.F., & Grivennikov, I.A. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60. PubMed

2. Levitskaya, N.G., Sebentsova, E.A., Andreeva, L.A., Alfeeva, L.Y., & Myasoedov, N.F. (2014). Characterization of binding sites for the heptapeptide Semax in rat brain membranes. Doklady Biochemistry and Biophysics, 459(1), 197-200. PubMed

3. Callahan, L.N., Neri, A., Lee, J.H., Poppe, A., & Bhattacharya, A. (2019). Melanocortin receptor involvement in neuroprotective and cognitive effects of heptapeptide Semax. Neurochemical Research, 44(6), 1432-1442. PubMed

4. Eremin, K.O., Kudrin, V.S., Saransaari, P., Oja, S.S., Grivennikov, I.A., Myasoedov, N.F., & Rayevsky, K.S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493-1500. PubMed

5. Ashmarin, I.P., Nezavibatko, V.N., Levitskaya, N.G., Koshelev, V.B., & Kamensky, A.A. (1997). Design and investigation of a nootropic analogue of adrenocorticotropin 4-10 lacking the D-amino acid substitution. Neuroscience and Behavioral Physiology, 27(2), 153-157. PubMed

6. Filippenkov, I.B., Stavchansky, V.V., Gubsky, L.V., Broszka, I., Remizov, M., Sudarkina, O.Y., Limborska, S.A., & Dergunova, L.V. (2020). Novel insights into the protective properties of Semax peptide in a rat model of ischemia-reperfusion. International Journal of Molecular Sciences, 21(12), 4484. PubMed

7. Tsvetkov, P.O., Cheglakov, I.B., Ovsepyan, A.A., Medvedeva, M.V., Telegin, G.B., & Kozin, S.A. (2016). Peripherally administered Semax peptide modulates gene expression of growth factors in rat brain. Journal of Molecular Neuroscience, 58(3), 399-404. PubMed

8. Stavchansky, V.V., Yuzhakov, V.V., Sevan’kaeva, L.E., Tsibulnikova, M.R., Butenko, E.V., Merkulova, N.A., Limborska, S.A., & Dergunova, L.V. (2011). The effect of Semax on morphological and proliferative properties of rat brain cells in conditions of experimental ischemia. Bulletin of Experimental Biology and Medicine, 152(2), 234-239. PubMed

9. Gusev, E.I., Skvortsova, V.I., Miasoedov, N.F., Nezavibat’ko, V.N., Zhdanova, I.V., & Alekseev, A.A. (1997). Efectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii, 97(6), 26-34. PubMed

10. Kaplan, A.Y., Kochetova, A.G., Nezavibathko, V.N., Rjasina, T.V., & Ashmarin, I.P. (1996). Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neuroscience Research Communications, 19(2), 115-123. PubMed

11. Nikiforova, M.A., Shadrina, M.I., Slominsky, P.A., Limborska, S.A., Myasoedov, N.F., & Dergunova, L.V. (2013). Antidepressant-like activity of Semax in models of depression and anxiety in rats. Journal of Neuroscience Research, 91(4), 542-551. PubMed

12. Inozemtseva, L.S., Dolotov, O.V., Andreeva, L.A., Grivennikov, I.A., & Myasoedov, N.F. (2006). Intranasal administration of the peptide Semax, which contains the ACTH(4-7) sequence, dramatically reduces the extent of brain damage and increases NGF expression in rat basal forebrain neurons after a photochemical stroke. Doklady Biological Sciences, 408, 229-232. PubMed

13. Grivennikov, I.A. (2008). Embryonic stem cells and the problem of directed differentiation. Biochemistry (Moscow), 73(13), 1438-1452. PubMed

14. Dergunova, L.V., Filippenkov, I.B., Stavchansky, V.V., Denisenko, E.V., Yuzhakov, V.V., Sevan’kaeva, L.E., Sudarkina, O.Y., Dmitrieva, V.G., Gubsky, L.V., Myasoedov, N.F., & Limborska, S.A. (2018). Genome-wide transcriptome analysis suggests that the neuroprotective peptide Semax prevents gene expression alterations induced by experimental ischemia in rat cerebral cortex and hippocampus. BMC Neuroscience, 19(1), 35. PubMed

15. Gusev, E.I., Martynov, M.Y., Kostenko, E.V., Petrova, L.V., & Bobyreva, S.N. (2018). The efficacy of semax in different periods of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii, 118(3), 61-68. PubMed

16. Kozin, S.A., Cheglakov, I.B., Ovsepyan, A.A., Telegin, G.B., Tsvetkov, P.O., & Makarov, A.A. (2013). Peripherally applied Semax regulates the expression of brain VEGF and its receptor in the cortex of rats with photochemical stroke. Journal of Peptide Science, 19(12), 743-748. PubMed

17. Miasoedov, N.F., Skvortsova, V.I., Tvorogova, T.V., Kovalenko, A.V., Zhuravleva, E.Y., & Limborska, S.A. (1999). Neuroprotective mechanisms of Semax in acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii, 99(5), 15-19. PubMed

18. Shadrina, M.I., Dolotov, O.V., Grivennikov, I.A., Slominsky, P.A., Andreeva, L.A., Myasoedov, N.F., & Limborska, S.A. (2001). Rapid induction of neurotrophin mRNA expression in rat neuroglial cell cultures by Semax, a synthetic derivative of adrenocorticotrophin. Neuroscience Letters, 308(3), 115-118. PubMed